



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 58016

**Title:** Autoimmunity as the comet tail of COVID-19 pandemic

**Reviewer's code:** 02207881

**Position:** Peer Reviewer

**Academic degree:** DVM, PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** France

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-07-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-07-05 15:42

**Reviewer performed review:** 2020-07-07 09:06

**Review time:** 1 Day and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

## SPECIFIC COMMENTS TO AUTHORS

Re:Autoimmunity as the comet tail of COVID-19 pandemic. A good manuscript and provides current knowledge on the additional complications of SARS-CoV-2 infection APL antibodies: they appear transiently in most of the infections and do not indicate autoimmune response. Follow-up is important to ensure whether response was transient or autoimmune response. Please discuss PIMS or MIS-C and include relevant references like: PMID: 32410760, 32499548, 32418446, 32598831, 32598830, 32493739, 32511692, 32527868, 32524957 Low incidence of severe COVID-19 in DMARDs-treated patients also suggest those molecules have potential therapeutic applications for the patient management. Some of the currently explored immunotherapies for COVID-19 like IL-6, IL-1 neutralization by monoclonal antibodies or intravenous immunoglobulin (IVIG) are also used for the management of autoimmune and inflammatory responses highlighted by the authors. These points could be discussed for the therapies. Some of the references include PMID: 32562483, 32376394, 32574265, 32499548, 32482597, [https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913\(20\)30173-9/fulltext](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30173-9/fulltext) Include a discussion on why autoimmune responses (either rheumatic, hematologic or neurologic) appear following COVID-19. ITP has been reported and need to be discussed (PMID: 32294340). Also, autoimmune hemolytic anemia (PMID: 32374906, 32460350, 32542444) and Evans Syndrome (PMID: 32420629)



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 58016

**Title:** Autoimmunity as the comet tail of COVID-19 pandemic

**Reviewer's code:** 02207881

**Position:** Peer Reviewer

**Academic degree:** DVM, PhD

**Professional title:** Full Professor

**Reviewer's Country/Territory:** France

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2020-07-04

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2020-08-04 10:12

**Reviewer performed review:** 2020-08-04 10:17

**Review time:** 1 Hour

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

All comments are addressed